Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > APGN Apexigen > Detailed Quotes

APGN Apexigen

Watchlist
1.680
-0.130-7.18%
Close  01/31 16:00 ET
1.750
+0.070+4.17%
Post Mkt Price 01/31 18:32 ET
High
1.830
Open
1.810
Turnover
393.83K
Low
1.600
Pre Close
1.810
Volume
230.20K
Market Cap
37.91M
P/E(TTM)
Loss
52wk High
31.350
Shares
22.57M
P/E(Static)
Loss
52wk Low
0.610
Float Cap
33.69M
Bid/Ask %
0.00%
Historical High
31.350
Shs Float
20.06M
Volume Ratio
0.59
Historical Low
0.610
Dividend TTM
--
Div Yield TTM
--
P/B
3.64
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.15%
Amplitude
12.70%
Avg Price
1.710
Lot Size
1
Float Cap
33.69M
Bid/Ask %
0.00%
Historical High
31.350
Shs Float
20.06M
Volume Ratio
0.59
Historical Low
0.610
Dividend TTM
--
P/B
3.64
Dividend LFY
--
Turnover Ratio
1.15%
Amplitude
12.70%
Avg Price
1.710
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Apexigen(formerly Brookline Capital Acquisition Corp.) is a clinical-stage biopharmaceutical company focused on developing innovative antibody therapies for the treatment of cancer with an immuno oncology focus. Apexigen has built a diversified pipeline of wholly owned and collaborative assets using its proprietary APXiMAB ? antibody discovery platform. The company's primary asset, Sotigalimab, is potentially the best-in-class and best-in-class CD40 agonist with unique epitope specificity and Fc receptor binding to achieve optimal therapeutic outcomes.
CEO: Dr. Xiaodong Yang, M.D.
Market: NASDAQ
Listing Date: 01/29/2021
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist